PTJ
INFI

Paul Tudor Jones’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Paul Tudor Jones’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-165,998
Closed -$224K – 1598
2016
Q4 		$224K Buy
165,998
+146,200
+738% +$191K 0.01% 1169
2016
Q3 		$31K Sell
19,798
-257,802
-93% -$396K ﹤0.01% 1385
2016
Q2 		$369K Buy
277,600
+218,000
+366% +$1.02M 0.01% 1039
2016
Q1 		$314K Buy
+59,600
New +$365K 0.01% 1264
2015
Q4 		– Sell
-21,600
Closed -$183K – 1895
2015
Q3 		$183K Buy
21,600
+2,700
+14% +$24.9K 0.01% 1355
2015
Q2 		$207K Buy
+18,900
New +$243K 0.01% 1324
2015
Q1 		– Sell
-12,679
Closed -$214K – 1661
2014
Q4 		$214K Sell
12,679
-3,484
-22% -$50.7K 0.01% 1237
2014
Q3 		$217K Buy
+16,163
New +$192K 0.01% 1159
2013
Q3 		– Sell
-20,240
Closed -$328K – 989
2013
Q2 		$328K Buy
+20,240
New +$626K 0.02% 512

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Paul Tudor Jones's INFI Position: Q1 2017 in Review

Paul Tudor Jones sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2017, closing a stake of 165,998 shares — an estimated $224K sold.

Paul Tudor Jones first reported a position in INFI in Q2 2013 and held it in 9 quarters. The position peaked at $369K in Q2 2016. 80 funds tracked by Wall St. Rank hold INFI as of Q1 2017.

  • Paul Tudor Jones reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Paul Tudor Jones sold 165,998 Infinity Pharmaceuticals, Inc. shares in Q1 2017, an estimated $224K.
  • Paul Tudor Jones first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 9 quarters.
  • Paul Tudor Jones's Infinity Pharmaceuticals, Inc. position peaked at $369K in Q2 2016.
  • 80 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2017.

Based on Tudor Investment Corp's 13F filing for Q1 2017, filed 15 May 2017.